Tag: GlobeNewswire

• After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded
• As of the same date, the Company had enrolled 30 patients
• Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027
• No safety signals were identified in the study
• Published case reports and the Company’s prospective expanded access study support the potential of tafenoquine-containing regimens in treatment-refractory, relapsing babesiosis, and additional data will be disclosed from this study in early November 2026
• Company sees a viable regulatory pathway for severe and/or treatment-refractory disease and will request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements, patient population, regulatory pathway, and post-marketing requirements

WASHINGTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it intends to conclude enrollment in its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects. The Company plans to unblind the study and report its primary and secondary endpoint results in January 2027, and to submit a request for a pre- supplemental New Drug Application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) that same month.

60 Degrees is the sponsor of the double-blind, randomized, multisite, placebo-controlled clinical trial entitled “Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis” (NCT06207370), which is evaluating the efficacy and safety of tafenoquine in treating severe babesiosis in humans. Patients were enrolled at multiple sites in the U.S., including Tufts Medical Center, Rhode Island Hospital, Yale University, Brigham and Women’s Hospital, and Westchester Medical Center.

The DSMB conducted an interim analysis of time to sustained clinical resolution of babesiosis, the study’s primary endpoint, and time to molecular clearance of Babesia parasites, a key secondary endpoint. Following its review, the DSMB recommended completing the initially planned enrollment of 33 patients. As of October 1, 2026, the Company had enrolled 30 subjects. Due to the marginal impact an additional three subjects would have on power to detect a difference on the study endpoints and the seasonality of babesiosis and its potential to delay unblinding by a year if additional subjects were to be recruited, the Company intends to proceed with final analysis of the enrolled population. The DSMB’s recommendation does not establish whether the study met its endpoints; those results will be determined following unblinding and final analysis. The DSMB analysis did not identify any safety issues.

A growing body of published case reports suggests that tafenoquine, administered in combination with atovaquone-containing regimens for at least eight weeks, may achieve a high cure rate in high-risk patients with treatment-refractory, relapsing babesiosis. Consistent with these reports, the Company has confirmed molecular cure, using a highly sensitive nucleic acid amplification test (NAT), in the first three patients enrolled in its expanded access study of tafenoquine combined with atovaquone-containing regimens in relapsing, treatment-refractory babesiosis (“Expanded Use in Persistent B. Microti Babesiosis” — NCT06478641). Final screening data from two additional patients are expected in early November 2026. Irrespective of the ultimate results of the severe babesiosis study to be reported in January, the Company believes an approval pathway based on case reports in the treatment-refractory population is possible.

The Company intends to request a pre-sNDA meeting with FDA to discuss the clinical evidence and data requirements for an sNDA submission for tafenoquine treatment of babesiosis. Should the data package be supported by literature and expanded access cases only, the Company plans to ask FDA to consider NAT-based molecular clearance as a surrogate endpoint reasonably likely to predict clinical benefit, potentially supporting an accelerated approval pathway. The Company would also propose a post-approval confirmatory study in an appropriate patient population. The availability of an accelerated approval pathway and the adequacy of the submission will be subject to FDA review.

No FDA-approved treatment or vaccine exists for human babesiosis. While tafenoquine is approved for the prevention of malaria, it is not currently approved by FDA for the treatment or prevention of babesiosis.

About Babesiosis

Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. It is often found as a co-infection of Lyme disease. Symptoms include fevers, chills, sweats, and fatigue. In severely immunocompromised patients, standard antimicrobial regimens can fail to clear infection, resulting in relapsing disease that may persist for months or years and has been associated with the emergence of antimicrobial-resistant Babesia strains. Incidence of babesiosis is rapidly rising, particularly in the Northeast, and the Centers for Disease Control and Prevention has advised that emergency room visits for tick bites are currently at historically high levels in many regions of the U.S.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA^® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA^® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:

Kristen Landon kristenlandon@60degreespharma.com

Investor Contact:

Patrick Gaynes patrickgaynes@60degreespharma.com

Two autonomous patrols lead the race, highlighting the operational readiness of UAE-developed autonomous robotics across urban and community environments

DUBAI, United Arab Emirates, Oct. 06, 2026 (GLOBE NEWSWIRE) — Micropolis Robotics (NYSE American: MCRP), a UAE-based developer of autonomous robotics and Physical AI solutions, participated in the second edition of the “Proud of UAE” Cycling Race organized by Dubai Police, with two DPR2 Autonomous Patrols (Dubai Police Robot 2) leading the cyclists at the front of the race.

The 80-kilometer race was organized by Dubai Police in cooperation with the UAE Cycling Federation, Dubai Sports Council and Dubai’s Roads and Transport Authority. The event formed part of a broader program of sporting and national initiatives designed to promote community well-being, physical activity and national pride.

The participation of the DPR2 Autonomous Patrols demonstrates how autonomous systems engineered for demanding public-safety and security applications can operate across a growing range of real-world environments. Their presence in a public sporting event also reflects the increasing integration of autonomous technology into urban and community settings, operating alongside people as part of everyday city life.

“Participating in the Proud of UAE race is particularly meaningful because it brings our technology directly into the community, operating in a real-world environment alongside Dubai Police and the public,” said Fareed Aljawhari, Founder and Chief Executive Officer of Micropolis Robotics. “Our strategic partnership with Dubai Police has enabled us to develop autonomous systems around real operational requirements. Every new application allows us to demonstrate the versatility and operational readiness of these technologies as we expand their potential across public safety, security, infrastructure and urban operations.”

The participation builds on Micropolis’ strategic partnership with Dubai Police to develop and advance autonomous robotic systems for public safety and urban security.

The DPR2 combines autonomous navigation, intelligent perception, 360-degree environmental awareness and advanced connectivity for operations across public safety, security and urban environments.

The technology has progressed from development and real-world testing to active field operations. Last year, the first deployment entered operational service at Global Village, establishing a foundation for the continued advancement and broader application of the platform.

The participation of the new DPR2 Autonomous Patrols in the Proud of UAE race builds on that progress, demonstrating the technology in another active, public-facing environment alongside Dubai Police and the community.

Micropolis designs, develops and manufactures its robotic technologies in the UAE, integrating autonomous mobility, artificial intelligence, mechatronics and connected systems into Physical AI platforms built for real-world operations.

About Micropolis AI Robotics

Micropolis Robotics is a UAE-based company specializing in the design, development, and manufacturing of unmanned ground vehicles (UGVs’), AI systems, and smart infrastructure for urban, security, and industrial applications. The Company’s vertically integrated capabilities cover everything from mechatronics and embedded systems to AI software and high-level autonomy.

For more information, please visit www.micropolis.ai.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning. Forward-looking statements represent Micropolis’ current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Contact: Info@Micropolis.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c7a863c9-6c19-4cb7-ae0c-12e38689d983

The Master Services Agreement is expected to add $24 million in new annual contracted revenue bringing the Company’s projected annual revenue to $47 million.

DOVER, Delaware, Oct. 06, 2026 (GLOBE NEWSWIRE) — Alpha Compute Corp. (Nasdaq: ALP) (“Alpha Compute” or the “Company”), a vertically integrated leader in Sovereign Super Intelligence, today announced the signing of a binding contract on September 30, 2026 for its ALPHA-02 cluster, delivering a state-of-the-art high density NVIDIA B300 GPU deployment located in a 100% hydropowered data center in Sweden.

The ALPHA-02 cluster delivers next-generation NVIDIA B300 compute capacity, purpose-built to accelerate high-density AI training and inference workloads. Securing this binding offtake agreement ahead of the cluster’s full deployment secures long-term utilization and highlights the sustained, escalating enterprise demand for sovereign, high-performance computing.

“Signing this agreement reflects our commitment to working closely with our clients to deliver tailored high-performance compute solutions that meet every technical and operational requirement,” said Yury Mitin, Chief Business Development Officer at Alpha Compute.

“Signing two major contracts over the past two quarters highlights the tremendous dedication and operational excellence of our team and key partners,” said Brittany Kaiser, Chief Executive Officer. “By combining seamless delivery with deep technical capabilities, we ensure our clients receive the enterprise-grade performance and reliability required for their most demanding AI workloads.”

About Alpha Compute Corp.
Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated technology company delivering High Performance Computing (HPC) and AI Confidential Compute. Alpha Compute’s mission is to empower clients, subsidiaries, and partners across critical sectors, including finance, defense, intelligence, and media with the essential framework required for secure, confidential computing environments. Alpha Compute operates globally with offices in New York, Los Angeles, Miami, Amsterdam, and Toronto. Alpha Compute is a proud founding partner of the Right2Compute Coalition. 

For more information, please visit www.alphacompute.ai or www.right2compute.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the expected revenue, financial projections, and economic impact of the ALPHA-02 offtake agreement; the anticipated timeline, performance, and capabilities of the ALPHA-02 and ALPHA-01 clusters; expected enterprise demand for high-density AI compute capacity; and Alpha Compute’s broader expansion and operational strategy across North America and Europe.

These statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Risks include, but are not limited to: supply chain disruptions affecting hardware delivery and deployment; changes in enterprise demand for AI computing; delays in infrastructure buildouts; regulatory developments regarding AI and data sovereignty; and general economic conditions. Alpha Compute expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

Investor & Media Contact
Alpha Compute Corp.
ir@alphacompute.ai
www.alphacompute.ai

CONTACT: ir@alphacompute.ai

TAMPA, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — Upexi, Inc. (NASDAQ: UPXI) (“Upexi” or the “Company”), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that Brian Rudick, Chief Strategy Officer, will participate in the following October 2026 investor conferences:

Maxim Growth Summit 2026
Date: October 12 – 14, 2026
Location: Hard Rock Hotel, New York, NY
Type: Investor Meetings

Webull Emerging & Innovative Companies Webinar
Date and Time: Wednesday, October 14, 2026, 1:00 PM ET
Type: Virtual Presentation
Webcast: https://ir.upexi.com/news-events/ir-calendar

LD Micro 20^th Annual Main Event
Date: October 19 – 21, 2026
Location: Luxe Sunset Blvd Hotel, Los Angeles, CA
Presentation Date and Time: Tuesday, October 20, 2026, at 3:00 PM PT
Presentation Location: Track 2
Type: Presentation & Investor Meetings
Webcast: https://ir.upexi.com/news-events/ir-calendar

To schedule a one-on-one meeting with Upexi’s management team, please email KCSA Strategic Communications at Upexi@KCSA.com.

About Upexi, Inc.
Upexi, Inc. (Nasdaq: UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion. In addition to benefiting from the potential price appreciation of Solana – the cryptocurrency of the leading high-performance blockchain – Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases. The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds over two million SOL. Upexi also continues to be a brand owner specializing in the development, manufacturing, and distribution of consumer products. Please see www.upexi.com for more information.

Follow Upexi on X – https://x.com/upexitreasury
Follow CEO, Allan Marshall, on X – https://x.com/upexiallan
Follow CSO, Brian Rudick, on X – https://x.com/thetinyant

Company Contact
Brian Rudick, Chief Strategy Officer
(203) 442-5391
brian.rudick@upexi.com

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
Upexi@KCSA.com

New triple-acid treatment booster is designed to help clarify, balance, and fade visible signs of blemish-prone skin while helping maintain hydration

LONG BEACH, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — SkinHealth Systems (NASDAQ: SKIN), a global medical aesthetics company and home to flagship brand Hydrafacial^®, announced the launch of the HydraClear™ Treatment Booster, a targeted solution to help clarify blemish-prone skin.

Powered by a targeted triple-acid blend of Salicylic Acid, Succinic Acid and Tranexamic Acid, HydraClear is designed to help clear pores, improve the appearance of congestion and visibly fade post-blemish marks, revealing clearer-looking, more balanced skin.

“HydraClear reflects where we are taking Hydrafacial treatments: beyond a premium facial to a more personalized skin health platform that can address a broader range of consumer needs,” said Pedro Malha, Chief Executive Officer of SkinHealth Systems. “We are focused on clinically meaningful innovation that expands what providers can deliver through Hydrafacial and gives them more ways to create visible results for their clients. HydraClear delivers on that strategy by addressing concerns correlated with blemish-prone skin – one of the most common and persistent skin health concerns.”

Clinically Tested for Continuous Visible Improvement
HydraClear was evaluated as part of a series of Deluxe Hydrafacial treatments for participants with blemish-prone skin. Following four treatments, the clinical investigator observed a 38% mean reduction in total blemishes and 81% of participants showed fewer visible blemishes.¹

Participants also reported noticeable improvements throughout the treatment series, including:

• 92% of participants reported improvement in at least one measured aspect of confidence or well-being related to the appearance of their skin after two treatments²
• 77% of participants reported their skin looked clearer and cleaner after two treatments.³
• 85% of participants said skin felt more hydrated after three treatments⁴
• 81% of participants saw more radiant-looking skin after three treatments4

“Acne is one of the most common reasons for a visit to the dermatologist, and its impact often extends beyond skin, affecting confidence, self-esteem and social interactions,” said Board-Certified Dermatologist Amy Forman Taub, MD, FAAD. “I led a clinical trial evaluating a treatment program with Hydrafacial hydrodermabasion, LED light therapy, and the HydraClear booster for blemish-prone skin. We were pleased to see significant improvement in as little as two to four weeks, with results sustained at 12 weeks. Many patients want faster results, whether they are seeking an option without medication or a treatment to complement their current medications. Based on these findings, I believe Hydrafacial treatments with the HydraClear booster will be a welcome addition for patients.”

Three Acids – Three Targeted Benefits
At the heart of the HydraClear Treatment Booster is a precisely engineered triple-acid formula designed to address visible signs of blemish-prone skin:

• Salicylic Acid exfoliates dead surface cells and breaks down excess oil.
• Succinic Acid helps soothe and refresh the look of skin while maintaining its natural balance.
• Tranexamic Acid helps visibly fade the appearance of post-blemish marks and supports a more even-looking skin tone.

The alcohol-free formula also includes antioxidants to help soothe the skin, glycerin and hydrators to help replenish skin hydration, and witch hazel to help reduce excess oil.

A Personalized Path Closer to Clear
HydraClear is delivered as part of Deluxe and Platinum Hydrafacial treatments, where it can be paired with blue LED light therapy as part of a personalized approach for blemish-prone skin.

HydraClear joins Hydrafacial’s portfolio of boosters designed to help address the most common skin concerns, including Hydralock HA, the brand’s leading hydrating booster, and HydraFillic with Pep9™, its leading anti-aging booster.

For more information and to find a provider near you, visit Hydrafacial.com.

¹Based on investigator assessment versus baseline at Week 12, four weeks after the fourth treatment, in a 12-week clinical study with 26 participants with mild-to-moderate acne with Hydrafacial Deluxe treatments performed at baseline, week 2, and week 4, with assessment at week 12. Hydrafacial LLC, 2026. Data on file. Individual results may vary.

²Based on participant-reported improvement versus baseline in at least one of five assessed psychosocial domains at Week 4, two weeks after two treatments, in a 12-week clinical study. N=26. Data on file at Hydrafaical. Individual results may vary.

³Based on participant self-assessment at week 4, two weeks after two treatments, in a 12-week clinical study. N=26. Hydrafacial LLC, 2026. Data on file. Individual results may vary.

⁴Based on participant self-assessment with Hydrafacial Deluxe treatments performed at baseline and week 2, with assessment at week 4. N=26. Data on file at Hydrafacial. Individual results may vary.

About SkinHealth Systems
SkinHealth Systems (NASDAQ: SKIN) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial™, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus™ microneedling and HydraScalp^® with Keravive™. SkinHealth Systems combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide. Learn more at skinhealthsystems.com or follow us on LinkedIn. Local providers can be found at hydrafacial.com/find-a-hydrafacialist.

Forward-Looking Statements
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding SkinHealth Systems Inc.’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside SkinHealth Systems Inc.’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Important factors that may affect actual results or outcomes include, among others: SkinHealth Systems Inc.’s ability to manage growth; SkinHealth Systems Inc.’s ability to execute its business plan; the success of HydraClear Treatment Booster’s launch and how its products are received amongst consumers and providers; potential litigation involving SkinHealth Systems Inc.; changes in applicable laws or regulations; the possibility that SkinHealth Systems Inc. may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent filings with the SEC such as on a Quarterly Report on Form 10-Q. There may be additional risks that the Company does not presently know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. SkinHealth Systems Inc. does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts:
Press: press@skinhealthsystems.com
Investors: IR@skinhealthsystems.com

Source: SkinHealth Systems

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/77a04405-f16b-4a1c-8f50-b237e65f4af0

BlackRock launches its first Canada Read on Retirement™ report, revealing new insights into the gap between Canadians’ confidence today and concerns about their financial security in retirement

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Canadians are confident about the progress they are making toward building retirement savings, but many are less certain about whether those savings will ultimately provide the security they need, according to BlackRock’s first Canada Read on Retirement™ report.

Among Canadians participating in a workplace retirement savings plan, 61% believe they are on track to achieve the lifestyle they expect in retirement and 65% are optimistic about their financial well-being over the next few years. Yet beneath that confidence, 68% worry about outliving their retirement savings, 72% say they may need to slow their retirement contributions in the next year, and 90% say they would feel more confident if their retirement plan helped smooth financial ups and downs throughout their lifetime.

The findings point to the next challenge for Canada’s retirement system: helping people turn the savings they have built into lasting retirement security. As people live longer, navigate greater uncertainty and take on more responsibility for their financial futures, retirement is being rewired. Retirement solutions need to evolve with them — helping people not only build savings but better understand how those savings can support them throughout retirement.

“Canada has built a strong foundation for helping people save for retirement, but our research shows there is still uncertainty about what comes next,” said Katherine Tweedie, Country Head of Canada, BlackRock. “Our Read on Retirement report highlights both the progress Canadians have made and the challenges they continue to face. As Canada’s largest manager of target date funds¹, we are leveraging these insights alongside our global retirement expertise and investment capabilities to continue to deliver solutions that support millions of Canadians throughout their retirement journey.”

Canada’s retirement ecosystem has helped millions of workers build long-term savings. In BlackRock’s view, the next opportunity is to help more Canadians turn those savings into lasting retirement security. Plan design, investment strategies, guidance and retirement-planning tools can all play a role in reducing the burden on individuals and helping them navigate the transition from accumulating savings to spending confidently in retirement.

The Canada Read on Retirement report brings BlackRock’s global retirement research to Canada, drawing on the firm’s deep retirement expertise, with more than half of the assets BlackRock manages globally supporting people in retirement.

“Canadians have made meaningful progress building retirement savings, but saving is only part of the equation,” said Nick Nefouse, Global Head of Retirement Solutions and Head of LifePath at BlackRock. “As people move through different stages of life, they face different retirement challenges, from balancing competing priorities early in their careers to making decisions about income, spending and risk later on. The opportunity for the industry is to deliver solutions that evolve with investors throughout that journey, helping turn long-term savings into lasting retirement security.”

_____________________________________________

¹ Canada’s largest target-date fund solution by assets under management”, Morningstar 2026 Canadian Target-Date Landscape, March 2026

Key Findings from the Survey:

Confidence today, questions about tomorrow

Canadians have done a good job prioritizing saving for retirement; however, questions remain about how long savings may last.

• Just over half (61%) of workers who participate in a retirement savings plan say they are ‘on track’ to achieve the lifestyle they expect and nearly two-thirds (65%) say they are optimistic about their financial well-being over the next few years.
• Confidence is higher in wealthier households – just 54% of participants living in households with an income of less than $75,000 said they are on track for retirement versus 72% of those with household incomes of $150,000 or more.
• At the same time, 68% of Canadians worry about outliving their retirement savings and 56% think they should be saving more.

Rising cost of living weighing on Canadian confidence

Despite many Canadians feeling overall confident about their savings, an average of 77% of Canadian participants say that higher inflation and market volatility have made it harder to stay on track. These challenges are strongest for those just starting their careers (Gen Z).

• 62% of Canadians say they expect rising living expenses to create financial challenges for them and nearly three-quarters (72%) of Canadian workers think they may need to slow their retirement contributions in the next year.
• Only around a quarter of Canadians are confident they won’t need to slow down their contributions this year.

A generational divide in retirement confidence

Another key finding is the generational split between savings confidence levels. BlackRock’s analysis suggests that as retirement challenges evolve over time, Canadians who are closer to retirement appear to be less confident about their retirement plans than those in the early days of their careers.

• Nearly three quarters (70%) of Gen Z participants feel they are on track for retirement, compared with 51% of Gen X participants – showing signs that confidence is shifting as retirement gets closer.
• Nearly 77% of mid-career participants expect they may need to reduce retirement contributions in the coming year and 67% of Gen X respondents say they worry about outliving their savings.
• One thing that rings true across all generations is that Canadians today worry their retirement will be shaped by a larger range of risks and decisions than previous generations had to face. 80% say “My generation won’t have the retirement certainty that past retirees had.”
• And for those currently in retirement, 82% say they are confident their savings will support them throughout their remaining journey.

From building savings to greater retirement security  

Despite strong confidence in savings, nearly three-quarters (74%) struggle to understand how today’s savings will actually fit into their long-term retirement plan. Canadians say they are looking for a clearer explanation of how savings will translate into spending, greater comfort through uncertain markets, and investment approaches that will evolve as their needs change.

• 65% are unsure how to calculate how much they will need to spend in retirement, in part because they don’t know what retirement living will look like for them.
• Participants are also looking for support to close the understanding gap: 83% say retirement spending and withdrawal-planning tools would be helpful, while 81% would like greater access to a financial professional for retirement-plan guidance.
• 90% of Canadians say they would feel more confident if their retirement plan helped smooth financial ups and downs throughout their lifetime and 92% said they would feel more at ease if their retirement savings adapted over time.

_____________________________________________

The survey was conducted by Escalent, an independent research firm, and reflects the experiences of Canadians across different parts of the retirement journey. A total of 1,009 Canadian workplace plan participants and 305 Canadian retirees were surveyed between May 25 and June 25, 2026.

About the 2026 BlackRock Canada Read on Retirement™ report
The 2026 BlackRock Canada Read on Retirement report provides insights from a research survey of workplace savers and retirees in Canada. The survey was conducted by Escalent, an independent research firm, and reflects the experiences of Canadians participating in the workplace retirement system and retirees. While the findings highlight the opportunities and challenges facing these Canadians, retirement outcomes among those without access to an employer-sponsored retirement plan may differ.

About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

Media Contact:
Sydney Punchard
Sydney.punchard@blackrock.com

BROOKFIELD, News, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brookfield Renewable (NYSE: BEP, BEPC; TSX: BEP.UN, BEPC) (“Brookfield Renewable”) will hold its Third Quarter 2026 Conference Call and Webcast on Wednesday, November 4, 2026 at 9:00 a.m. ET to discuss results and business initiatives.

Results will be released on Wednesday, November 4, 2026 at approximately 7:00 a.m. ET and will be available on our website at https://bep.brookfield.com under “Press Releases”.

Participants can join by conference call or webcast:

Conference Call

• Please pre-register for conference call by clicking: BEP Q3 2026 Conference Call
• Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

• Please join and register for the webcast by clicking: BEP Q3 2026 Webcast

Brookfield Renewable

Brookfield Renewable operates one of the world’s largest publicly traded platforms for renewable power and sustainable solutions. Our renewable power portfolio consists of hydroelectric, wind, utility-scale solar, distributed solar, and storage facilities and our sustainable solutions assets include our investment in a leading global nuclear services business and a portfolio of investments in carbon capture and storage capacity, agricultural renewable natural gas, materials recycling and eFuels manufacturing capacity, among others.

Investors can access the portfolio either through Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: BEP.UN), a Bermuda-based limited partnership, or Brookfield Renewable Corporation (NYSE, TSX: BEPC), a Canadian corporation.

Brookfield Renewable is the flagship listed energy company of Brookfield Asset Management, a leading global alternative asset manager headquartered in New York, with over $1 trillion of assets under management.

Contact information:
Media:	Investors:
Marie Fuller	Alex Jackson
Senior Vice President – Corporate Communications	Vice President – Investor Relations
(44) 207-408-8375	(416)-484-8525
marie.fuller@brookfield.com	alexander.jackson@brookfield.com

ANDOVER, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global leader in aerospace and defense electronics, today introduced RES One™, its next-generation rugged edge server platform built with enhanced modularity to accelerate deployment, streamline technology insertion, and reduce sustainment costs over long-duration mission lifecycles.

RES One is purpose-built for demanding edge compute missions in harsh and remote environments, including maritime, airborne, and ground systems, as well as commercial and industrial edge applications. It addresses one of the most persistent challenges facing long-life military and industrial systems: the widening gap between rapid commercial technology evolution and multi-decade program lifecycles. Its modular, future-ready design significantly reduces costly redesign cycles traditionally required when upgrading edge compute hardware in systems that may be deployed for 20 years or more. RES One is also designed for expedited deployment, leveraging Mercury’s vertically integrated manufacturing and established supply chain, designed to achieve lead times significantly shorter than the industry’s typical 6-12 month delivery timelines for ruggedized edge compute platforms.

The initial RES One portfolio includes both 1U and 2U chassis featuring stable, long-term external interfaces and internal modularity built on open standards architectures, allowing customers to refresh CPUs, accelerators, storage, and security modules as technology advances. RES One also features Mercury’s RelianceOne™ edge security platform, purpose-built to meet defense and commercial cybersecurity and resiliency requirements across embedded, containerized, virtual, and standard user environments.

“RES One represents a fundamental shift in the deployment and lifecycle management of edge computing systems, with a simplified approach that gives program managers the ability to rapidly field and upgrade systems that leverage the most advanced commercial hardware, software, and security solutions,” said Ken Hermanny, Mercury’s Senior Vice President of Processing Technologies. “By combining open architectures with long-term form fit function stability, we are providing our customers a platform that can meet urgent delivery timelines and be relied upon for decades without lengthy redesign cycles that drain resources and threaten mission readiness.”

Mercury will debut the RES One server at the 2026 AUSA Annual Meeting and Exposition, booth 1445, from October 12-14, 2026.

Mercury Systems – Innovation that matters^®
Mercury Systems is a global leader in aerospace and defense electronics, providing breakthrough capabilities in signal and data processing. With a four-decade legacy of innovation that spans silicon to systems and RF front ends to effectors, Mercury accelerates commercial technology adoption to deliver powerful and secure mission-critical processing solutions to the edge. Mercury is headquartered in Andover, Massachusetts, and has multiple locations worldwide. To learn more, visit mrcy.com. (Nasdaq: MRCY)

Forward-Looking Safe Harbor Statement 
This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s focus on enhanced execution of the Company’s strategic plan. You can identify these statements by the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, cost increases, our inability to increase production and deliver products on time and with appropriate quality, continued funding of defense programs, the timing and amounts of such funding, general economic and business conditions, including unforeseen weakness in the Company’s markets, effects of any U.S. federal government shutdown or extended continuing resolution, effects of increasingly volatile geopolitical events and regional conflicts, competition, changes in technology and methods of marketing, delays in or cost increases related to completing development, engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in, or in the U.S. government’s interpretation of, federal export control or procurement rules and regulations, including tariffs, changes in, or in the interpretation or enforcement of, environmental rules and regulations, market acceptance of the Company’s products, shortages or delays in receiving components, supply chain delays or volatility for critical components, production delays or unanticipated expenses including due to quality issues or manufacturing execution issues, failure to meet contractual performance specifications, adherence to required manufacturing standards, capacity underutilization, increases in scrap or inventory write-offs, failure to achieve or maintain manufacturing quality certifications, such as AS9100, failure to achieve or maintain qualified business systems, such as those required by the DFARS, adverse findings in government audits or investigations, the impact of supply chain disruption, inflation and labor shortages, among other things, on program execution and the resulting effect on customer satisfaction, inability to fully realize the expected benefits from acquisitions, restructurings and operational efficiency initiatives or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, effects of shareholder activism, increases in interest rates, changes to industrial security and cyber-security regulations and requirements and impacts from any cyber or insider threat events, including the risks from heightened, persistent, and increasingly sophisticated nation-state level cyberattacks and emerging threats associated with agentic AI-enabled cyber tools, changes in tax rates or tax regulations, changes to interest rate swaps or other cash flow hedging arrangements, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, litigation, including the state law claim related to our settled federal securities class action lawsuit, unanticipated costs under fixed-price service and system integration engagements, and various other factors beyond our control. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended July 3, 2026 and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

INVESTOR CONTACT
Tyler Hojo, CFA
Vice President, Investor Relations
Tyler.Hojo@mrcy.com

MEDIA CONTACT
Turner Brinton
Senior Director, Corporate Communications
Turner.Brinton@mrcy.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/299cdf52-a873-438e-9261-56c5b7601338

NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.

In addition, the Company also announced today that it has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA).

“We are excited to have our ANTICIPATE-NASH analysis selected for oral presentation and the recognition of our Baveno and ELF analysis as a Poster of Distinction. These selections reflect not only the depth of the NAVIGATE trial datasets but also underscores the importance of non-invasive assessments in diagnosis of portal hypertension in patients with MASH cirrhosis who are at increased risk of developing serious complications such as varices. This represents the fourth consecutive major liver meeting where the Company has been selected for an oral presentation, and I want to thank our entire team led by Dr. Khurram Jamil, our Chief Medical Officer, for their efforts in this achievement. We have also submitted the registrational Phase 3 protocol, an important step forward in the advancement of our belapectin program for patients who today have no approved treatment options,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics.

Presentation Details
Oral Presentation

Title: ANTICIPATE-NASH Risk Stratification Predicts Variceal Development in Compensated MASH Cirrhosis: Results from the NAVIGATE Trial
Publication Number: 0253
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 8, 2026, 9:15 am – 9:30 am MST

Poster Presentations

Poster of Distinction:
Title: Baseline Baveno Portal Hypertension and ELF Risk Stratification Predict Variceal Development in Compensated MASH Cirrhosis: Findings from the NAVIGATE Trial
Session: MASLD/MASH – Therapeutics: New Agents and Approved/Available Agents
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 7, 2026 at 12:00 pm – 1:00 pm MST

Title: Correlation of Baveno VII and ANTICIPATE-NASH Noninvasive Models with HVPG in Patients with MASH Cirrhosis: Findings from a Phase 2b Belapectin Trial
Session: Portal Hypertension and Other Complications of Cirrhosis
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 5, 2026 at 12:00 pm – 1:00 pm MST

The presentations will be available for viewing by AASLD attendees and will be posted on our website under the “Events & Presentations” page shortly after the congress.
        
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com. 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com 

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

Company and President Frank Ingriselli Also Highlighted in Recent CNBC Interview

JAKARTA, INDONESIA AND DANVILLE, CA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Indonesia Energy Corporation (NYSE American: INDO) (“IEC”), an oil and gas exploration and production company focused on Indonesia, today announced, that its President Frank Ingriselli led a delegation in early October to IEC’s Kruh Block in Sumatra, Indonesia to celebrate oil production from the recently drilled K-29 well.

The delegation also visited the nearby WK-5 well location, where site setup and rig assembly (using the same rig that drilled the K-29 well) are actively underway. Preparations are also ongoing for the anticipated spudding of the WK-5 well by the end of this month.

The WK-5 well is planned to be drilled to a depth of approximately 5,200 feet, significantly deeper than the K-29 well, which was drilled to approximately 3,400 feet. WK-5 is designed to test additional formations identified through IEC’s extensive 3-D seismic program, including a potential natural gas-bearing formation. K-29 and WK-5 are each located within IEC’s 63,000-acre Kruh Block on the island of Sumatra.

A video showing oil production from K-29 and the delegation’s visit to the WK-5 site can be viewed at the following link: https://www.youtube.com/watch?v=uW2igiI9p4U

In addition, IEC announced that Mr. Ingriselli and IEC were recently featured in a CNBC interview as part of a segment highlighting innovative microcap companies. The CNBC interview can be viewed here: https://youtu.be/uYdi3KfvFNs

These videos, along with an interview with Frank Ingriselli from the recent EnerCom conference, in Denver, Colorado are also available on IEC’s website at: https://ir.indo-energy.com

Mr. Ingriselli commented “I was extremely pleased to lead our delegation to the Kruh Block to celebrate production from K-29 and to visit the WK-5 location as we prepare to spud this exciting new well. WK-5 will be drilled significantly deeper than K-29 and is designed to test additional formations identified by our 3-D seismic program. We believe these formations have the potential to add significant value to IEC.

“With the drilling equipment and crews already mobilized at the Kruh Block, we are also taking advantage of this opportunity to conduct a hydraulic fracturing operation on K-29 with the goal of maximizing production. K-29 is currently producing with a jack-pump and dewatering, with production currently consisting of approximately 60% oil and a 40% water cut and separated into our storage tanks and is being combined with our other producing wells and sold to Pertamina, the Indonesian state oil and gas company.

“We are excited by the progress at Kruh and look forward to the upcoming drilling of WK-5 as we continue working to increase production and unlock the potential of our assets in Indonesia,” concluded Mr. Ingriselli.

About Indonesia Energy Corporation Limited

Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (195,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements

All statements in this press release, the videos presented herein, and related statements of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, the words “explore,” “could,” “estimates,” “seek,” “believes,” “hopes,” “understand,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” “aim,” “goal,” “may” and similar conditional expressions related to the future are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release, other than those of historical fact, about an action, event or development, are forward-looking statements. In this press release, forward-looking statements include, without limitation those related to the timing for, and results of, 2026 and other drilling and anticipated production activities at IEC’s Kruh Block as well as the price of oil and natural gas, which changes daily and could lower over time. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of significant risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of IEC’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed on April 29, 2026, and other filings with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov and IEC’s website at https://ir.indo-energy.com/sec-filings/. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:
Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com